Fusion of the human immunodeficiency virus type 1 Tat protein transduction domain to thymidine kinase increases bystander effect and induces enhanced tumor killing in vivo

Human Gene Therapy

Volumn 16, Issue 12, 2005, Pages 1389-1403

  Tasciotti, Ennio ^a   Giacca, Mauro ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; TAT11 THYMIDINE KINASE FUSION PROTEIN; THYMIDINE KINASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL KILLING; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN B16F10; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; KAPOSI SARCOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN DOMAIN; SUICIDE GENE THERAPY; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BYSTANDER EFFECT; DISEASE MODELS, ANIMAL; GENE PRODUCTS, TAT; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; HIV-1; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; SARCOMA, KAPOSI; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 29244469125     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1389     Document Type: Article

References (48)

1. AGBARIA, R., CANDOTTI, F., KELLEY, J.A., HAO, Z., JOHNS, D.G., COONEY, D.A., BLAESE, R.M., and FORD, H., JR. (2001). Biosynthetic ganciclovir triphosphate: Its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. Biochem. Biophys. Res. Commun. 289, 525-530.
2. ALBINI, A., PAGLIERI, I., ORENGO, G., CARLONE, S., ALUIGI, M.G., DEMARCHI, R., MATTEUCCI, C., MANTOVANI, A., CAROZZI, F., DONINI, S., and BENELLI, R. (1997). The β-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcomaderived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 11, 713-721.
3. ALBINI, A., MARCHISONE, C., DEL GROSSO, F., BENELLI, R., MASIELLO, L., TACCHETTI, C., BONO, M., FERRANTINI, M., ROZERA, C., TRUINI, M., BELARDELLI, F., SANTI, L., and NOONAN, D.M. (2000). Inhibition of angiogenesis and vascular tumor growth by interferonproducing cells: A gene therapy approach. Am. J. Pathol. 156, 1381-1393.
4. BENELLI, R., ADATIA, R., ENSOLI, B., STETLER-STEVENSON, W.G., SANTI, L., and ALBINI, A. (1994). Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: Implications for an anti-angiogenic therapy. Oncol. Res. 6, 251-257.
5. BI, W.L., PARYSEK, L.M., WARNICK, R., and STAMBROOK, P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
6. BOYKINS, R.A., ARDANS, J.A., WAHL, L.M., LAL, R.B., YAMADA, K.M., and DHAWAN, S. (2000). Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice. Peptides 21, 1839-1847.
7. CAFARO, A., TITTI, F., FRACASSO, C., MAGGIORELLA, M.T., BARONCELLI, S., CAPUTO, A., GOLETTI, D., BORSETTI, A., PACE, M., FANALES-BELASIO, E., RIDOLFI, B., NEGRI, D.R., SERNICOLA, L., BELLI, R., CORRIAS, F., MACCHIA, I., LEONE, P., MICHELINI, Z., TEN HAAFT, P., BUTTO, S., VERANI, P., and ENSOLI, B. (2001). Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19, 2862-2877.
8. CARUSO, M., SALOMON, B., ZHANG, S., BRISSON, E., CLAVEL, F., LOWY, I., and KLATZMANN, D. (1995). Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology 206, 495-503.
9. CHANG, H.C., SAMANIEGO, F., NAIR, B.C., BUONAGURO, L., and ENSOLI, B. (1997). HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11, 1421-1431.
10. CHEN, M.S., SUMMERS, W.P., WALKER, J., SUMMERS, W.C., and PRUSOFF, W.H. (1979). Characterization of pyrimidine deoxyribonucleoside kinase (thymidine kinase) and thymidylate kinase as a multifunctional enzyme in cells transformed by herpes simplex virus type 1 and in cells infected with mutant strains of herpes simplex virus. J. Virol. 30, 942-945.
11. COHEN, J.L., BOYER, O., SALOMON, B., ONCLERCQ, R., CHARLOTTE, F., BRUEL, S., BOISSERIE, G., and KLATZMANN, D. (1997). Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89, 4636-4645.
12. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
13. DEGREVE, B., JOHANSSON, M., DE CLERCQ, E., KARLSSON, A., and BALZARINI, J. (1998). Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: Molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. J. Virol. 72, 9535-9543.
14. FERRARI, A., PELLEGRINI, V., ARCANGELI, C., FITTIPALDI, A., GIACCA, M., and BELTRAM, F. (2003). Caveolae-mediated internalization of extracellular HIV-1 Tat fusion proteins visualized in real time. Mol. Ther. 8, 284-294.
15. FIDLER, I.J., and NICOLSON, G.L. (1978). Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma. Isr. J. Med. Sci. 14, 38-50.
16. FILLAT, C., CARRIO, M., CASCANTE, A., and SANGRO, B. (2003). Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr. Gene Ther. 3, 13-26.
17. FITTIPALDI, A., and GIACCA, M. (2005). Transcellular protein transduction using the Tat protein of HIV-1. Adv. Drug Deliv. Rev. 57, 597-608.
18. FITTIPALDI, A., FERRARI, A., ZOPPE, M., ARCANGELI, C., PELLEGRINI, V., BELTRAM, F., and GIACCA, M. (2003). Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278, 34141-34149.
19. FRANK, K.B., CHIOU, J.F., and CHENG, Y.C. (1984). Interaction of herpes simplex virusinduced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J. Biol. Chem. 259, 1566-1569.
20. HAKANSSON, S., and CAFFREY, M. (2003). Structural and dynamic properties of the HIV-1 Tat transduction domain in the free and heparin-bound states. Biochemistry 42, 8999-9006.
21. JOHANSSON, M., BRISMAR, S., and KARLSSON, A. (1997). Human deoxycytidine kinase is located in the cell nucleus. Proc. Natl. Acad. Sci. U.S.A. 94, 11941-11945.
22. KIANMANESH, A.R., PERRIN, H., PANIS, Y., FABRE, M., NAGY, H.J., HOUSSIN, D., and KLATZMANN, D. (1997). A "distant" by-stander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8, 1807-1814.
23. KLATZMANN, D. (1996). Gene therapy for metastatic malignant melanoma: Evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum. Gene Ther. 7, 255-267.
24. KLATZMANN, D., CHERIN, P., BENSIMON, G., BOYER, O., COUTELLIER, A., CHARLOTTE, F., BOCCACCIO, C., SALZMANN, J.L., and HERSON, S. (1998a). A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther. 9, 2585-2594.
25. KLATZMANN, D., VALERY, C.A., BENSIMON, G., MARRO, B., BOYER, O., MOKHTARI, K., DIQUET, B., SALZMANN, J.L., and PHILIPPON, J. (1998b). A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 9, 2595-2604.
26. KOKORIS, M.S., SABO, P., ADMAN, E.T., and BLACK, M.E. (1999). Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6, 1415-1426.
27. MAR, E.C., CHIOU, J.F., CHENG, Y.C., and HUANG, E.S. (1985). Inhibition of cellular DNA polymerase α and human cytomegalo-virus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl) guanine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J. Virol. 53, 776-780.
28. MARCONI, P., TAMURA, M., MORIUCHI, S., KRISKY, D.M., NIRANJAN, A., GOINS, W.F., COHEN, J.B., and GLORIOSO, J.C. (2000). Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther. 1, 71-81.
29. MATTHEWS, T., and BOEHME, R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3), S490-S494.
30. MCKINNEY-FREEMAN, S.L., JACKSON, K.A., CAMARGO, F.D., FERRARI, G., MAVILIO, F., and GOODELL, M.A. (2002). Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc. Natl. Acad. Sci. U.S.A. 99, 1341-1346.
31. OHNO, T., GORDON, D., SAN, H., POMPILI, V.J., IMPERIALE, M.J., NABEL, G.J., and NABEL, E.G. (1994). Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781-784.
32. + T cells. J. Exp. Med. 198, 569-580.
33. PACKER, R.J., RAFFEL, C., VILLABLANCA, J.G., TONN, J.C., BURDACH, S.E., BURGER, K., LAFOND, D., MCCOMB, J.G., COGEN, P.H., VEZINA, G., and KAPCALA, L.P. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92, 249-254.
34. QIAO, J., BLACK, M.E., and CARUSO, M. (2000). Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum. Gene Ther. 11, 1569-1576.
35. RAINOV, N.G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389-2401.
36. RAMESH, R., MARROGI, A.J., MUNSHI, A., ABBOUD, C.N., and FREEMAN, S.M. (1996). In vivo analysis of the "bystander effect": A cytokine cascade. Exp. Hematol. 24, 829-838.
37. RUSNATI, M., COLTRINI, D., ORESTE, P., ZOPPETTI, G., ALBINI, A., NOONAN, D., D'ADDA DI FAGAGNA, F., GIACCA, M., and PRESTA, M. (1997). Interaction of HIV-1 Tat protein with heparin: Role of the backbone structure, sulfation, and size. J. Biol. Chem. 272, 11313-11320.
38. RUSNATI, M., TULIPANO, G., URBINATI, C., TANGHETTI, E., GIULIANI, R., GIACCA, M., CIOMEI, M., CORALLINI, A., and PRESTA, M. (1998). The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J. Biol. Chem. 273, 16027-16037.
39. SACCHETTI, A., CAPPETTI, V., MARRA, P., DELL'ARCIPRETE, R., EL SEWEDY, T., CRESCENZI, C., and ALBERTI, S. (2001). Green fluorescent protein variants fold differentially in prokaryotic and eukaryotic cells. J. Cell. Biochem. 81(Suppl. 36), 117-128.
40. SHAND, N., WEBER, F., MARIANI, L., BERNSTEIN, M., GIANELLA-BORRADORI, A., LONG, Z., SORENSEN, A.G., and BARBIER, N. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10, 2325-2335.
41. TANAKA, M., FRAIZER, G.C., DE LA CERDA, J., CRISTIANO, R.J., LIEBERT, M., and GROSSMAN, H.B. (2001). Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther. 8, 139-148.
42. TASCIOTTI, E., ZOPPE, M., and GIACCA, M. (2003). Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-aminoacid peptide from HIV-1 Tat. Cancer Gene Ther. 10, 64-74.
43. TYAGI, M., RUSNATI, M., PRESTA, M., and GIACCA, M. (2001). Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276, 3254-3261.
44. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, LR. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
45. WADHWA, P.D., ZIELSKE, S.P., ROTH, J.C., BALLAS, C.B., BOWMAN, J.E., and GERSON, S.L. (2002). Cancer gene therapy: Scientific basis. Annu. Rev. Med. 53, 437-452.
46. WADIA, J.S., STAN, R.V., and DOWDY, S.F. (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310-315.
47. ZACCHIGNA, S., ZENTILIN, L., MORINI, M., DELL'EVA, R., NOONAN, D.M., ALBINI, A., and GIACCA, M. (2004). AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 11, 73-80.
48. ZENTILIN, L., MARCELLO, A., and GIACCA, M. (2001). Involvement of cellular doublestranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J. Virol. 75, 12279-12287.